Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
2
40%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (50.0%)
Phase 42 (50.0%)

Trials by Status

recruiting240%
completed360%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

NCT06853951
recruiting

Evaluation and Management of Cardio Toxicity in Oncologic Patients

NCT02818517
completedphase_4

Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

NCT00344513
completedphase_4

Reducing Total Cardiovascular Risk in an Urban Community

NCT00241904
completedphase_3

Occluded Artery Trial (OAT)

NCT00004562

Clinical Trials (5)

Showing 5 of 5 trials
NCT06853951Phase 3

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

Recruiting
NCT02818517

Evaluation and Management of Cardio Toxicity in Oncologic Patients

Recruiting
NCT00344513Phase 4

Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

Completed
NCT00241904Phase 4

Reducing Total Cardiovascular Risk in an Urban Community

Completed
NCT00004562Phase 3

Occluded Artery Trial (OAT)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5